EM
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade | Cellular and molecular life sciences |  | 2025 | 182 | 96 | ||
| Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence | Nature biomedical engineering | | 2025 | 21 | 14 | ||
| PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | | 2024 | 299 | 275 | ||
| Brain Metastases from Genito-Urinary Cancers in the Canton of Geneva (Switzerland) : Study of Incidence, Management and Outcomes | Cancers | | 2024 | 91 | 186 | ||
| Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial | Nature cancer |  | 2024 | 379 | 3 | ||
| PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma | | 2023 | 240 | 529 | |||
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | | 2023 | 325 | 162 | ||
| Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread | Neurology Genetics | | 2021 | 336 | 102 | ||
| Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) | JCI insight | | 2021 | 263 | 202 | ||
| Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells | Communications Biology | | 2021 | 344 | 213 | ||
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | | 2020 | 484 | 310 | ||
| Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma | OncoImmunology | | 2020 | 459 | 309 | ||
| Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients | Frontiers in Oncology | | 2020 | 353 | 162 | ||
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | | 2019 | 852 | 634 | ||
| Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients | Cancers | | 2019 | 371 | 215 | ||
| Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models | OncoImmunology | | 2018 | 434 | 1 | ||
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | | 2018 | 667 | 378 | ||
| Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing | PloS one | | 2016 | 670 | 682 | ||
| Ipilimumab-related hypophysitis may precede severe CNS immune attack | Annals of Oncology | | 2016 | 462 | 0 |
